EP 3810595 A1 20210428 - OGA INHIBITOR COMPOUNDS
Title (en)
OGA INHIBITOR COMPOUNDS
Title (de)
OGA-INHIBITOR-VERBINDUNGEN
Title (fr)
COMPOSÉS INHIBITEURS D'OGA
Publication
Application
Priority
- EP 18382450 A 20180620
- EP 2019066390 W 20190620
Abstract (en)
[origin: WO2019243531A1] The present invention relates to O-GIcNAc hydrolase (OGA) inhibitors of formula (I). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C90RF72 mutations. RB is a radical selected from the group consisting of (b-1) to (b-4).
IPC 8 full level
C07D 401/14 (2006.01); A61K 31/4427 (2006.01); A61K 31/4436 (2006.01); A61K 31/4439 (2006.01); A61K 31/444 (2006.01); A61P 25/28 (2006.01); C07D 409/14 (2006.01); C07D 413/14 (2006.01)
CPC (source: EP US)
C07D 401/14 (2013.01 - EP US); C07D 403/14 (2013.01 - US); C07D 409/14 (2013.01 - EP US); C07D 413/14 (2013.01 - EP US)
Citation (search report)
See references of WO 2019243531A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
WO 2019243531 A1 20191226; AU 2019291097 A1 20201217; CA 3102903 A1 20191226; CN 112334462 A 20210205; EP 3810595 A1 20210428; JP 2021528412 A 20211021; MA 52938 A 20210428; US 2021300900 A1 20210930
DOCDB simple family (application)
EP 2019066390 W 20190620; AU 2019291097 A 20190620; CA 3102903 A 20190620; CN 201980041380 A 20190620; EP 19732990 A 20190620; JP 2020570577 A 20190620; MA 52938 A 20190620; US 201917253446 A 20190620